GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

avutometinib   Click here for help

GtoPdb Ligand ID: 11867

Synonyms: Avmapki Fakzynja (avutometinib + defactinib co-pack) | CH-5126766 | CH5126766 | compound 1 [PMID: 24900832] | RG-7304 | RO-5126766 | RO5126766 | VS-6766
Approved drug PDB Ligand
avutometinib is an approved drug
Compound class: Synthetic organic
Comment: Avutometinib (CH5126766; Ro5126766) is a small molecule that acts to inhibit p-MEK and p-ERK downstream of the c-RAF/MEK1 interaction [1,3]. It inhibits the proliferation of BRAFV600E and KRAS mutant cell lines in vitro. Avutometinib is orally active.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

avutometinib is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 144.69
Molecular weight 471.1
XLogP 2.96
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CNS(=O)(=O)Nc1nccc(c1F)Cc1c(=O)oc2c(c1C)ccc(c2)Oc1ncccn1
Isomeric SMILES Fc1c(nccc1Cc1c(=O)oc2c(c1C)ccc(c2)Oc1ncccn1)NS(=O)(=O)NC
InChI InChI=1S/C21H18FN5O5S/c1-12-15-5-4-14(31-21-25-7-3-8-26-21)11-17(15)32-20(28)16(12)10-13-6-9-24-19(18(13)22)27-33(29,30)23-2/h3-9,11,23H,10H2,1-2H3,(H,24,27)
InChI Key LMMJFBMMJUMSJS-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
RO5126766 was advanced to oncology clinical trials. The FDA granted accelerated approval for the combination of avutometinib and defactinib in May 2025, indicated to treat KRAS-mutated recurrent low-grade serous ovarian cancer (following previous systemic therapy).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04720417 Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma Phase 2 Interventional Thomas Jefferson University
NCT03681483 RO5126766 for Patients With Advanced KRAS-Mutant Lung Cancer Phase 1 Interventional Memorial Sloan Kettering Cancer Center
NCT03875820 Phase I Trial of VS-6063 and RO5126766. Phase 1 Interventional Institute of Cancer Research, United Kingdom
NCT05074810 Phase 1/2 Study of VS-6766 + Sotorasib in G12C NSCLC Patients Phase 1/Phase 2 Interventional Verastem, Inc.
NCT06072781 A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer Phase 3 Interventional Verastem, Inc. 2